Table 2.
Characteristic | GIST (n=49) |
LMS (n=47) |
SRC (n=50) |
p |
---|---|---|---|---|
Male, n (%) | 29 (59) | 13 (28) | 28 (56) | 0.003 |
Age, median (range), yr | 55 (35–79) | 57 (23–75) | 54 (4–79) | 0.709 |
Disease free interval <12 months, n (%) | 26 (53) | 22 (49) | 26 (52) | 0.807 |
Tumor size, median (range), mm | 40 (6–250) | 29 (6–148) | 50 (3–230) | 0.006 |
Number of tumors, median (range) | 2 (1–9) | 1 (1–10) | 1 (1–10) | 0.161 |
Major hepatectomy >3 segments, n (%) | 22 (45) | 25 (53) | 28 (56) | 0.519 |
Concomitant RFA, n (%) | 13 (27) | 10 (21) | 7 (14) | 0.301 |
R1 resection, n (%) | 2 (4) | 2 (4) | 4 (8) | 0.627 |
Adjuvant treatment, n (%) | 41 (84) | 27 (57) | 28 (56) | 0.005 |
Tyrosine kinase inhibitor, n (%) | 39 (80) | 0 | 1 (2) | < 0.001 |
GIST: gastrointestinal stromal tumor; LMS: leiomyosarcoma; SRC: sarcoma of other or indeterminate origin; RFA: radiofrequency ablation; R1 resection: viable tumor cells < 1 mm from the resection margin.